Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs

Araújo, Tatiane da Silva; Filho, Adriano José Maia Chaves; Monte, Aline Santos; Queiroz, Ana Isabelle de Góis; Cordeiro, R.C.; Machado, Michel de Jesus Souza; Lima, Ricardo; Lucena, David Freitas de; Maes, Michaël; Macêdo, Danielle Silveira

doi:10.1016/j.jpsychires.2016.09.017

Cited by 43 publications

(24 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theories and hypotheses have linked these neurotransmitter systems to a) risk of schizophrenia, b) symptomatology, c) disease progression d) response to therapy. The knowledge of these links have been employed in a number of preclinical studies, and have resulted in the development of validated pharmacologic and genetic disease models; which allow the replication of behavioural, neuro-developmental [11], neuro-morphological [113][114][115][116] and neurochemical phenotypes similar to those observed in humans [103]; and the investigation of novel therapies [117][118][119][120][121][122].…”

Section: Neurotransmitter/ Receptor Dysfunctions In Schizophreniamentioning

confidence: 99%

“…Melatonin has been linked to the aetiopathogenesis of schizophrenia [298]; and an emerging area in schizophrenia research focuses on the impact of immunomodulatory drugs like melatonin [119], with studies assessing the therapeutic potential of exogenous administration of melatonin. In a recent study using a ketamine model of schizophrenia in mice, significant improvements in behavioural and brain oxidative stress parameters were recorded following melatonin administration as a sole agent [119,121] or adjunct [299]. The findings of the studies are in line with earlier observations that administration of melatonin may augment the efficacy of antipsychotics through suppression of neuroinflammation; and its potent antioxidative effects [300].…”

Section: (C) Antioxidants Hormonals Trace Elements and Immunomodulamentioning

confidence: 99%

See 1 more Smart Citation

Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management

Onaolapo¹,

Onaolapo²

2018

app

View full text Add to dashboard Cite

Schizophrenia is a chronic, debilitating and complex neuropsychiatric disorder which is known to be characterised by impairments in perception of reality, cognition, interpersonal relationships, mood and social/work function; and influenced by genes and the environment. Our understanding of the aetiology of schizophrenia and theories seeking to explain the accompanying changes in brain chemistry and structure has continued to undergo revisions, largely due to new insights from preclinical and clinical research. In this review, we discuss the evolution of our understanding of schizophrenia aetiopathogenesis as it relates to disease phenotype, symptom management and drug discovery. We also examine the important roles played by interactions between brain neurotransmitters and their receptors in disease expression and symptom management; and discuss how newer chapters in the management of the disease are being opened through the development and identification of newer disease-modifying and modulating agents.

show abstract

Section: Neurotransmitter/ Receptor Dysfunctions In Schizophreniamentioning

confidence: 99%

Section: (C) Antioxidants Hormonals Trace Elements and Immunomodulamentioning

confidence: 99%

Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management

Onaolapo¹,

Onaolapo²

2018

app

View full text Add to dashboard Cite

show abstract

“…In many cases, these effects have only been recently discovered and they work through no unified mechanism or disease model [ 19 , 21 , 22 ]. Finally, the third group consists of D-amino acids that are inert within the brain but have interesting derivative molecules or metabolites in the brain [ 23 , 24 , 25 , 26 , 27 ]. Table 1 and Table 2 list the D-amino acids discussed in this review and summarizes how they enter the body, their biologically active derivatives, and gives a short description of the amino acid.…”

Section: Introductionmentioning

confidence: 99%

Advances in D-Amino Acids in Neurological Research

Seckler

Lewis

2020

IJMS

View full text Add to dashboard Cite

D-amino acids have been known to exist in the human brain for nearly 40 years, and they continue to be a field of active study to today. This review article aims to give a concise overview of the recent advances in D-amino acid research as they relate to the brain and neurological disorders. This work has largely been focused on modulation of the N-methyl-D-aspartate (NMDA) receptor and its relationship to Alzheimer’s disease and Schizophrenia, but there has been a wealth of novel research which has elucidated a novel role for several D-amino acids in altering brain chemistry in a neuroprotective manner. D-amino acids which have no currently known activity in the brain but which have active derivatives will also be reviewed.

show abstract

“…This mental disorder is widely studied in the scientific community using the animal model induced by chronic administration of ketamine, an antagonist drug of the N‐methyl‐ d ‐aspartate receptor (NMDAr), which mimics the pathophysiology of the disease, since there is a decrease in the NMDAr activity at the level of the central nervous system (CNS) …”

Section: Introductionmentioning

confidence: 99%

“…[1,4] This mental disorder is widely studied in the scientific community using the animal model induced by chronic administration of ketamine, an antagonist drug of the N-methyl-D-aspartate receptor (NMDAr), which mimics the pathophysiology of the disease, since there is a decrease in the NMDAr activity at the level of the central nervous system (CNS). [2,3,5] Due to this, the treatment of patients with schizophrenia is performed with antipsychotics that act on this dysfunction, divided into two groups, typical and atypical. [1] This one is also known as second-generation antipsychotics, and it has been shown to be quite effective in treatment, since they reveal a decrease in adverse effects.…”

Section: Introductionmentioning

confidence: 99%

Standardized extract of Erythrina velutina Willd. attenuates schizophrenia-Like behaviours and oxidative parameters in experimental animal models

Dias

Almeida

Vasconcelos

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives To study the effects of the standardized extract from the leaves of Erythrina velutina in behavioural and oxidative parameters in the ketamine‐induced schizophrenia model. Methods Mice received ketamine (KET) or saline for 7 days. From 8th to 14th day, the animals received Erythrine (Eryt) (100, 200 or 400 mg/kg) or olanzapine (Olanz), 1 h after KET administration. At 14th day, 30 min after the last administration of KET, the open‐field and pre‐pulse inhibition (PPI) tests were performed. Then, the animals were sacrificed and the prefrontal cortex (PFC), hippocampus (HC) and striatum (ST) were dissected for the oxidative tests. Key findings Ketamine increased spontaneous locomotor activity and grooming. KET decreased the PPI, which was reversed by combining it with Eryt or olanzapine. KET decreased GSH concentration in PFC and ST this was reversed by Eryt. KET increased MDA concentration in PFC and HC this was reversed by Eryt. Eryt and Olanzapine reduced MDA concentration in ST when compared to KET group. Nitrite concentration was reduced by administration of KET in the PFC. Conclusions These results demonstrate that the standardized extract of E. velutina can prevent behavioural symptoms and oxidative stress induced by repeated doses of KET.

show abstract

Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs

Cited by 43 publications

References 90 publications

Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management

Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management

Advances in D-Amino Acids in Neurological Research

Standardized extract of Erythrina velutina Willd. attenuates schizophrenia-Like behaviours and oxidative parameters in experimental animal models

Contact Info

Product

Resources

About